Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs BigBearai Holdings Inc (BBAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs BigBearai Holdings Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288 (market cap $39.89B), while BigBearai Holdings Inc trades at $3.07 (market cap $1.57B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 25.4× BigBearai Holdings Inc's market cap. Which is the better fit depends on your goals.
| ALNY | BBAI | |
|---|---|---|
Market Cap | $39.89B | $1.57B |
Sector | Health | Technology |
52-Week High | $491.22 | $8.91 |
52-Week Low | $278.09 | $3.05 |
Enterprise Value | $38.15B | $1.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
BigBear.ai (BBAI) trades at $3.27, down 1.51% amid bearish technical signals. The company shows persistent losses with a -226.69% net income margin despite steady $127M revenue. Recent Dutch approval for airport security technology highlights growth potential, but high SG&A expenses and negative cash flow from operations remain concerns. Technical indicators show oversold conditions with RSI at 25.86, though moving averages signal continued bearish pressure.
BBAI faces significant execution risks with negative profitability metrics, though analyst consensus leans neutral with 75% hold ratings. The stock's outlook depends on converting AI contract wins into sustainable profitability, with current valuation appearing rich given ongoing losses. Near-term catalysts include Q2 2026 earnings and defense contract execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About BigBearai Holdings Inc
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →
